Suivre
Abonner Novo Nordisk

Novo Nordisk

Filtre
  • 12.05.2014 – 11:55

    NovoEight® provides long-term reduction of bleeding in people with haemophilia A

    Copenhagen, Denmark (ots/PRNewswire) - For healthcare media only, not for US, UK or Spanish journalists Today, Novo Nordisk announced new phase 3 interim data from its guardian(TM)2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight(R) (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term ...

  • 28.03.2014 – 10:12

    Novo Nordisk Launches 'Cities Changing Diabetes' to Fight Urban Diabetes

    Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announces the launch of 'Cities Changing Diabetes', an ambitious new partnership programme to fight the urban diabetes challenge. The 'Cities Changing Diabetes' programme will first be launched in Mexico City with other cities in North America, Europe and Asia soon to follow. To view the Multimedia News Release, ...

  • 04.12.2012 – 11:01

    Novo Nordisk to Create the World's First All-diabetes Professional Cycling Team

    Bagsværd, Denmark (ots/PRNewswire) - ? Novo Nordisk today announced a unique partnership to form Team Novo Nordisk, a global sports team with more than 100 cyclists, triathletes and runners who all have diabetes, spearheaded by the world's first all-diabetes pro-cycling team. To view the Multimedia News Release, please click: ...

  • 28.04.2011 – 09:40

    Novo Nordisk Increased Operating Profit by 24% in the First Quarter of 2011 (28 April 2011)

    Bagsvaerd, Denmark (ots/PRNewswire) - Sales increased by 15% in Danish kroner and by 11% in local currencies. - Sales of modern insulins increased by 14% (11% in local currencies). - Victoza(R) sales of DKK 1,098 million (growth of 191% in local currencies). - Sales of NovoSeven(R) increased by 6% (4% in local currencies). - Sales in North America increased by 16% (14% ...

  • 01.03.2004 – 13:10

    Switzerland is first to launch new diabetes therapy - Levemir® (insulin detemir)

    Geneva (ots) - Novo Nordisk Switzerland announced today that Levemir® (insulin detemir), a novel, predictable basal insulin analogue with a unique mechanism of prolonging action (scientifically known as protraction), is available for people with type 1 and type 2 diabetes in Switzerland today. The Swiss launch is just the beginning of an exciting global roll-out of ...